key: cord-0737645-i964iwx7
authors: Sánchez‐García, V.; Hernández‐Quiles, R.; de‐Miguel‐Balsa, E.; Docampo‐Simón, A.; Belinchón‐Romero, I.; Ramos‐Rincón, J.M.
title: Are the chilblain‐like lesions observed during the COVID‐19 pandemic due to severe acute respiratory syndrome coronavirus 2? Systematic review and meta‐analysis
date: 2021-10-05
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17672
sha: 8b7dc32319e7cc72c2083e537c16f4421a3b8d88
doc_id: 737645
cord_uid: i964iwx7

The expansion of the COVID‐19 pandemic has been accompanied by numerous reports of chilblain‐like lesions (CLL) in different countries; however, the pathogenesis of these lesions is still unclear. This systematic review and meta‐analysis aimed to assess the prevalence of COVID‐19 (diagnosed using PCR and/or serology) in patients with CLL. We undertook a literature search in PubMed, Embase, and Scopus (to 15 March 2021), including studies that reported on the number of patients with CLL with positive PCR and/or serology for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) or with a clinical suspicion of COVID‐19. Regardless of data heterogeneity, a random‐effects model was used to pool prevalence estimates. The meta‐analysis included 63 original studies, involving 2919 cases of CLL. A subgroup of these patients underwent diagnostic tests for COVID‐19 (PCR: n = 1154, 39.5%; serology: n = 943, 32.3%). The pooled prevalence of COVID‐19 in the overall sample and in the subgroup who were tested for COVID‐19 was, respectively: (i) positive PCR: 2.6% [95% confidence interval (CI) 1.9% to 3.4%] and 5.5% (95% CI, 3.7–7.7%); (ii) positive serology for SARS‐CoV‐2: 7.2% (95% CI, 4.7–10.2%) and 11.8% (95% CI, 7.9–16.3%); and (iii) positive PCR and/or serology, 15.2% (95% CI, 10.4–20.7%) and 7.5% (95% CI, 5.1–10.3%). Altogether, a small proportion of diagnostic tests for SARS‐CoV‐2, both PCR and serologies, show positive results in patients with CLL.

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19, has been spreading globally since it first emerged in Wuhan (China) in December 2019. 1 As the pandemic has expanded its reach, numerous cutaneous manifestations associated with COVID-19 have been reported, 2 encompassing a diverse range of clinical presentations, from skin rashes and chilblain-like lesions (CLL) to purplish lesions and skin necrosis. 3 Since the pandemic began, there has been an uptick in reports of cases of acral, chilblain-like lesions. Different studies have suggested or investigated a potential association between these lesions and infection from the SARS-CoV-2 virus. However, their pathophysiology remains unclear and widely debated, because despite the temporal association between the outbreak of CLL and the COVID-19 pandemic, only a fraction of patients with CLL have tested positive for SARS-CoV-2.

The primary objective of this systematic review and metaanalysis is to assess the prevalence of SARS-CoV-2 infection (as diagnosed by PCR and/or serological antibody testing) in patients with CLL. These results can inform an evaluation of whether these CLL 4 or COVID toes are truly associated with COVID-19. • Intervention: diagnostic tests for COVID-19 (PCR and/or serology) and study of the epidemiological characteristics in patients with CLL.

• Comparator: not applicable. • Outcomes: percentage of patients with CLL who were diagnosed or presented symptoms consistent with infection by SARS-CoV-2; positivity rate of PCRs and serologies in patients with CLL.

• Study design. Observational studies involving at least five patients diagnosed with CLL and specified how many participants presented positive diagnostic tests for COVID-19 (PCR and/or serology) or had a clinical suspicion of SARS-CoV-2 infection.

No date restrictions were applied. Following the PRISMA procedure, 5 duplicate articles were excluded. Two review authors (V.S.G. and R.H.Q.) independently screened the title and abstract of records yielded by the search to classify the reference as potentially relevant or irrelevant. After retrieving the full text of all potentially relevant papers, the two authors independently checked them against the review's inclusion criteria. Disagreements were resolved by consensus.

Two review authors (V.S.G. and R.H.Q.) independently extracted and summarized data for each included article on an Excel spreadsheet, and a third author (J.M.R.R.) checked them. For each included record, the following information was collected: first author, journal of publication, date of publication, country of study, language of publication, study design, sample size, proportion of men and women, patient age (mean/median and range), number of patients considered close contacts of people diagnosed or suspected of having COVID-19, total PCRs performed, total positive and negative PCRs, total serologies performed, total positive and negative serologies, total patients diagnosed with COVID-19, case definition (patients with compatible clinical signs and patients diagnosed with COVID-19), and patients with symptoms compatible with infection by SARS-CoV-2.

Two review authors independently assessed the methodological quality of the studies included in the meta-analysis, using Quality Assessment Tool for Case Series Studies of National Heart, Lung and Blood Institute (NHLBI) according to the study design. 6 Disputes were resolved by consensus. The seven domains assessed were: bias due to confounding, bias in selection of participants into the study, bias in measurement of interventions, bias due to departures from intended interventions, bias due to missing data, bias in measurement of outcomes, and bias in selection of the reported result.

Confirmed cases of COVID-19 were defined based on a positive PCR for SARS-CoV-2 (nasopharyngeal or stool swab) and/or positive serology for SARS-CoV-2 antibodies. Suspected cases of COVID-19 were those in patients that did not undergo a COVID-19 diagnostic test or who presented a negative test but met European Centre for Disease Prevention and Control (ECDC) criteria for a possible COVID-19 infection. 7 Participants were considered contacts of COVID-19 cases when they had been in contact with a patient who had tested positive for SARS-CoV-2 via nasopharyngeal or stool swab and/ or had a positive serology for SARS-CoV-2 antibodies. People who had been in contact with suspected cases of COVID-19 (based on ECDC criteria 7 ) were considered to be possible contacts of COVID-19 patients.

We used descriptive statistics to present the data, including counts, ranges, and percentages, along with a narrative synthesis summarizing results in text and tables. Prevalence estimates were calculated as the proportion of patients with CLL and positive diagnostic tests for COVID-19, over both the total sample of patients with CLL and the subgroup of patients with CLL who underwent PCR and/or serology. The prevalence meta-analysis was performed using Statsdirect statistical software v. 3.3.5 (Merseyside, UK). Forest plots were constructed to graphically represent the pooled prevalence for positive PCRs and serological tests for COVID-19 in patients with CLL, with respect to the total number of diagnostic tests performed, and prevalence was expressed as a percentage with 95% confidence intervals (CIs). The Stuart-Ord method (inverse double arcsine square root) was used to calculate the 95% coefficient intervals and create effect diagrams.

The heterogeneity of included studies was assessed using the I 2 statistic (95% CI) and the Q statistic. I 2 values over 50% indicate heterogeneous data. The random-effects model was applied regardless of heterogeneity because of the substantial heterogeneity expected between studies. Risks of reporting bias or small study effects were analysed graphically using funnel plots and statistically using Egger's regression. P values of <0.10 on Egger's test were considered to indicate statistically significant reporting bias.

The searches in the three bibliographic databases (PubMed, Embase, and Scopus) yielded a total of 875 articles. Following deduplication and screening of titles and abstracts, 165 full-text records were retrieved and assessed against eligibility criteria. The final meta-analysis included 63 records that met all inclusion criteria; 52 other studies were excluded from the metaanalysis due to a sample size of fewer than five patients (see PRISMA flow chart in Fig. 1) . Table 1 presents the characteristics of included studies. Most (84.1%) were case reports in patients with CLL. Seven other studies (11.1%) used a retrospective study design, while the remaining three (4.8%) were prospective. Studies took place in Spain (n = 23, 36.5%), Italy (n = 19, 30.2%), France (n = 12, 19.1%), the USA (n = 7, 11.1%), Belgium (n = 1, 1.6%), and Australia (n = 1, 1.6%).

The number of included participants ranged from 5 8-11 to 534. 12 For the meta-analysis, we extracted data on 2919 cases of skin lesions classified on the clinical spectrum of CLL from December 2019 to March 2021. Participants included 1092 (37.4%) women and 1200 (41.1% men); five large studies involving 627 patients (21.5%) did not report participants' gender. [12] [13] [14] [15] [16] Participants' ages varied by study, with the age ranging from 0 17-20 to 100 years 21 among all participants. The mean age in studies reporting this variable ranged from 10.6 years 22 to 62 years. 9 Overall, the mean age for the sample was 20.9 years.

A total of 502 patients (17.2%) were considered close contacts of people with a confirmed diagnosis or high clinical suspicion of COVID-19 infection. Of the 2919 cases with CLL, 1154 (39.5%) underwent PCRs and 943 (32.3%) serology.

In quality assessment, 41 studies were ranked as having good quality, 19 studies ranked as having fair quality and three studies were ranked as having poor quality (Table S1 ).

Pooled prevalence of positive diagnostic tests for COVID-19 Table 2 shows the main findings of the meta-analysis for prevalence of positive COVID-19 diagnostic tests among the total patients with CLL and in the subgroup who underwent some diagnostic tests for COVID-19.

In the study of positive PCRs, five studies were excluded from the meta-analysis: two for not presenting any positive PCRs 19,23 and three for not having performed any PCRs in the sample. 9, 24, 25 The pooled prevalence of COVID-19-positive PCRs among all patients with CLL was 2.6% (95% CI, 1.9-3.4%; Fig. 2 ), with low heterogeneity and no asymmetry apparent in the funnel plot, corroborated by Egger's test (Fig. S1 ). The pooled prevalence of positive PCRs in patients with CLL who underwent PCR testing for COVID-19 was 5.5% (95% CI, 3.7-7.7%), with moderate heterogeneity and asymmetry in the funnel plot.

In the meta-analysis for prevalence of positive serology, 15 studies were excluded for not having performed serological testing in their participants. 10, [18] [19] [20] 22, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] The pooled prevalence of positive serologies for SARS-CoV-2 antibodies in all patients with CLL was 7.2% (95% CI, 4.7-10.2%; Fig. 3 ). Data showed high heterogeneity and asymmetry in the funnel plot (Fig. S2 ). The pooled prevalence for positive serological tests in patients with CLL who underwent serological testing was 11.8% (95% CI, 7.9-16.3%), with high heterogeneity and asymmetry in the funnel plot.

In the meta-analysis pooling prevalence estimates for any positive COVID-19 diagnostic test in patients with CLL, four studies were excluded: two for not specifying the number of patients with CLL who were diagnosed with COVID-19 (by PCR and/or serology), 12, 35 and two for not performing either test or not specifying how many tests were done. 19, 23 The pooled prevalence of patients with CLL who were diagnosed with a SARS-CoV-2 infection by PCR and/or serology was 15.2% (95% CI, 10.4-20.7%; Fig. 4 ), with high heterogeneity and asymmetry in the funnel plot (Fig. S3 ). The pooled prevalence for positive PCRs and/or serologies in patients with CLL who underwent a diagnostic test for COVID-19 was 7.5% (95% CI, 5.1-10.3%), with high heterogeneity and asymmetry in the funnel plot.

Our meta-analysis shows a low prevalence of positive PCRs among patients with CLL and only a slightly higher prevalence of positive serologies for SARS-CoV-2 antibodies. Altogether, the pooled prevalence of positive PCRs among patients with CLL was 2.6%, and of positive serologies, 7.2%. Although the results show that 502 patients were named contacts of people with suspected or confirmed COVID-19 infections, the number of people infected was much lower.

The CLL lesions appear relatively late in the course of COVID-19, often during the convalescent phase, from 1 to 5 weeks after onset of the first symptoms of infection. 36, 37 This could explain the negative results of the PCRs; however, the prevalence estimates based on antibody testing-while showing slightly higher results-were still quite low.

Despite the temporal association between the increased cases of CLL and the COVID-19 pandemic, the low proportion of positive diagnostic tests for SARS-CoV-2 in these patients does not support the hypothesis that there is a relationship between the two pathologies. In 1996, Fredericks & Relman called for a reconsideration of Koch's postulates for analysing the causal relationship between a microorganism and an infectious disease, with seven criteria that the patients with these acral lesions do not fulfil. 38 However, different theories have emerged to explain this discrepancy. One is that the low prevalence of positive diagnostic tests for COVID-19 in these patients could be due to the generation of IgA antibodies against the respiratory mucus, the site of the first contact with the virus. 13 This would justify the lack of memory in the immune response (self-limiting disease) and explain why only a few cases present an IgG memory. This Records excluded (n = 102):

• Same population as another study (n = 3) • Did not report total PCRs or serologies performed nor the number of patients with COVID-19 symptoms (n = 10) • Clinical studies that did not report COVID toes (n = 37) • Case reports/series involving <5 patients (n = 52)

Included Figure 1 PRISMA flow chart for study selection. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. 79 Range: (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) N/A 2 (40%)/0 (0%) 0 (0%)/0 (0%) Confirmed: 0 Suspected: 1 F: 4 (80%) M: 1 (20%) theory opens the door to studying a possible role for neutralizing IgA antibodies in the resolution of the infection, especially in patients with mild symptoms. 13 A few publications have reported IgA-positive serologies against SARS-CoV-2 in patients with CLL. 39, 40 However, these results must be interpreted with caution because the high sensitivity of these antibodies could cause some false positives. 41 Other authors have considered CLL to be the cutaneous expression of a strong innate immune type 1 interferon (IFN-1) response. This would contribute to the clearance of the virus prior to production of immunoglobulins, leading to failed serological detection. [41] [42] [43] The up-regulation of the IFN-1 pathway would cause severe microangiopathy and trigger the generation of CLL in patients with a genetic predisposition. 35, 44 However, the absence of cutaneous or extra-cutaneous symptoms in other interferonopathies raises unanswered questions around this hypothesis. 41 Specific T cells have been detected in serologically negative individuals with a history of asymptomatic or mildly symptomatic COVID-19, leading some authors to suggest that skin manifestations could induce a weak response at a serological level but a robust one at the cellular level. 24 Unfortunately, there are no tests that measure the activation of T cells available in clinical practice. Another possibility is that PCRs and serologies are negative when the viral inoculum is small. The patients would not develop symptoms, and the serological response would be of such low intensity as to be undetectable with the currently available tests. Some studies have reported that serological responses tend to be lower in young people; in such cases, the only manifestations of COVID-19 would be endothelitis and a propensity for thrombosis in the small distal veins of the extremities. 45 This theory is supported by the tendency for CLL to appear in young patients with few to no symptoms and who do not require hospitalization. 36 Our results provide further corroboration for this hypothesis, with our meta-analysis showing that the mean age of patients with CLL and COVID-19 is 20.9 years.

Another potential explanation that has been proposed is a more indirect relationship, provoked by behavioural changes brought on by lockdowns and quarantines, specifically, sedentary behaviours and the exposure of bare feet to cold interior environments. Children and adolescents were among the most affected populations by these restrictions, as they could not go to school and spent considerable time sitting in front of a television or computer. The lack of mobility could have reduced circulation and the subsequent appearance of chilblains. 42 Improvements in CLL cases following thermal protection measures and the relaxation of confinement restrictions support this hypothesis. 39, 41, 46 However, these lesions are not among the skin signs observed in paraplegic or wheelchair-bound patients. 42 Our meta-analysis has some limitations, the most important of which is the high between-study heterogeneity, evidenced by the I 2 values in the analyses. The patients were not all subjected to the same type of diagnostic tests for COVID-19, and most sample sizes were small. Generally, the funnel plots for each meta-analysis indicate reporting bias, backed up by significant results on Egger's test, suggesting that there have been small studies with negative results that have not been published. There may also be cases that have been reported in more than one series. 47 Furthermore, most studies did not systematically perform diagnostic tests for COVID-19 in all patients, but rather only collected tests that had already been undertaken. Thus, there is a risk of overestimation bias regarding the prevalence of COVID-19 in the total number of individuals tested, as in practice, PCRs or serologies are more likely to be performed in people with systemic symptoms that are compatible with COVID-19 or in those who are contacts of infected patients than in people without these characteristics.

By contrast, the main issue of the studies carried out is the low rate of patients fully investigated for COVID-19 status, due to the low rate of symptoms and the absence of the need for hospitalization in the most COVID-19 patients with CLL, as we have previously commented. So, we cannot be sure that, although this article shows a negative relationship between CLL and COVID-19, it can be excluded.

In sum, our meta-analysis does not definitively confirm the relationship between CLL and COVID-19. There is a need for further studies of high methodological quality that perform serological tests for COVID-19 that are sufficiently sensitive and specific as well as correctly timed in order to detect a possible seroconversion.

Additional Supporting Information may be found in the online version of this article: Table S1 . Quality Assessment of Included Studies: Quality Assessment Tool for Case Series Studies of National Heart, Lung and Blood Institute (NHLBI).

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Dermatologic manifestations and complications of COVID-19

Cutaneous manifestations of COVID-19: a systematic review

Acral findings during the COVID-19 outbreak: chilblain-like lesions should be preferred to acroischemic lesions

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Study Quality Assessment Tools

European Centre for Disease Prevention and Control. Case definition and European surveillance for COVID-19, as of 2

Major cluster of paediatric "true" primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown

Perniosis during the COVID-19 pandemic: negative anti-SARS-CoV-2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS-CoV-2

COVID toes in stay-at-home adolescents: an epiphenomenon

characteristics, laboratory findings and outcomes in acro-ischemia in covid-19 patients

Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations

Presencia de anticuerpos antifosfol ıpidos IgA en pacientes con lesiones perni oticas asociadas a COVID-19

Chilblains and COVID-19: further evidence against a causal association

No antibody response in acral cutaneous manifestations associated with COVID-19?

Acute acral cutaneous manifestations during the COVID-19 pandemic: a single-centre experience

No SARS-CoV-2 antibody response in 25 patients with pseudo-chilblains

Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review

Therapy for probable COVID-19 associated erythema pernio-like lesions in pediatric age. Case report

Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak

Novel outbreak of acral lesions in times of COVID-19: a description of 74 cases from a tertiary university hospital in Spain

The management of the outbreak of acral skin manifestations in asymptomatic children during COVID-19 era

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Association between COVID-19 and chilblains: a case-control study

Relapse of chilblain-like lesions during the second wave of coronavirus disease 19

Chilblains in children in the setting of COVID-19 pandemic

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic

Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak

The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases

Acral cutaneous lesions in the time of COVID-19

Histopathological features of Chilblain-like lesions developing in the setting of the COVID-19 pandemic

A new dermoscopic pattern for chilblain-COVID-19-like skin lesions in adolescents

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic

Chilblain-like lesions and COVID-19 infection: a prospective observational study at Spain's ground zero

Going viral: a brief history of Chilblain-like skin lesions

Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing

Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Negative SARS-CoV-2 PCR in patients with chilblain-like lesions

COVID toes: where do we stand with the current evidence?

Chilblain-like lesions and COVID-19: second wave, second outbreak

BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2

A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2?

Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic

No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain

Pitfalls of possible reporting of same patients with COVID-19 in dermatology journals

Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic

High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreak

Clinical medicine skin manifestations in COVID-19: prevalence and relationship with disease severity

Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: a multicenter study on 10 patients

Immunological and virological profile of children with chilblain-like lesions and SARS-CoV

Management of pernio-like cutaneous manifestations in children during the outbreak of COVID-19

Are SARS-CoV-2 IgA antibodies in paediatric patients with chilblain-like lesions indicative of COVID-19 asymptomatic or paucisymptomatic infection?

Le lesioni acro-ischemiche nei bambini-adolescenti in tempi di CoViD-19: dal micro-ambiente da clausura all'interferone

Acral lesions in a pediatric population during the COVID-19 pandemic: a case series of 36 patients from a single hospital in Spain

Response to "No evidence of SARS-CoV-2 infection by PCR or serology in children with pseudochilblain

Pernio-like eruption associated with COVID-19 in skin of color

Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblainslike lesions during the COVID-19 pandemic

Acral skin eruption observed during SARS-CoV-2 pandemic: possible keratolysis exfoliativa with red palms and soles

All that glisters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with chilblain-like lesions

Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: histologic and serologic findings from a new immunoassay

New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus

Chilblain-like lesions during the COVID-19 pandemic: a serological study on a case series

COVID-19 and outbreak of chilblains: are they related?

Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection

COVID toes"'): histologic, immunofluorescence, and immunohistochemical study of 17 cases

Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries

Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19

Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Chilblain-like lesions on feet and hands during the COVID-19 Pandemic

Chilblain and acral purpuric lesions in Spain during COVID confinement: retrospective analysis of 12 cases

Acute acral eruptions in children during the COVID-19 pandemic: characteristics of 103 children and their family clusters

Cold and COVID: recurrent pernio during the COVID-19 pandemic

Cutaneous manifestations of COVID-19 in the Franche-Comt e region of France: a monocentric study

Pseudo-chilblain lesions and COVID-19: a controversial relationship

Skin manifestations during the COVID-19 pandemic in the pediatric emergency department

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

We would like to thanks Dr. Hector Pinargote for his contribution in editing the analysis figures and Meggan Harris for her help in translating this manuscript.